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Abstract
Purpose—The combination of a platinum and taxane are standard of care for many cancers, but
the utility is often limited due to debilitating neurotoxicity. We examined whether single
nucleotide polymorphisms (SNPs) from annotated candidate genes will identify genetic risk for
chemotherapy-induced neurotoxicity.
Patients and Methods—A candidate-gene association study was conducted to validate the
relevance of 1261 SNPs within 60 candidate genes in 404 ovarian cancer patients receiving
platinum/taxane chemotherapy on the SCOTROC1 trial. Statistically significant variants were then
assessed for replication in a separate 404 patient replication cohort from SCOTROC1.
Results—Significant associations with chemotherapy-induced neurotoxicity were identified and
replicated for four SNPs in SOX10, BCL2, OPRM1, and TRPV1. The Population Attributable
Risk for each of the four SNPs ranged from 5-35%, with a cumulative risk of 62%. According to
the multiplicative model, the odds of developing neurotoxicity increase by a factor of 1.64 for
every risk genotype. Patients possessing 3 risk variants have an estimated odds ratio of 4.49
(2.36-8.54) compared to individuals with 0 risk variants. Neither the four SNPs nor the risk score
were associated with progression free survival or overall survival.
Conclusions—This study demonstrates that SNPs in four genes have a significant cumulative
association with increased risk for the development of chemotherapy-induced neurotoxicity,
independent of patient survival.
INTRODUCTION
Combination chemotherapy with a platinum-containing drug (cisplatin, carboplatin,
oxaliplatin) and a taxane (docetaxel, paclitaxel) have demonstrated improved outcomes for
many malignancies including ovarian and lung cancer.(1-3) However, the efficacy of this
therapy is often compromised because of debilitating toxicities, especially neurotoxicity.
Despite initial tumor control, cancer patients treated with chemotherapy often must
discontinue therapy due to peripheral neuropathy. There has also been the suggestion that
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presence of neuropathy may be associated with better progression-free survival in ovarian
cancer.(4)
There have been many attempts to circumvent or minimize the neurotoxic effects of the
chemotherapeutic agents.(5) Interventions using neuroprotectant agents including the
administration of reduced glutathione(6), magnesium and calcium(7, 8), vitamin E(9), and
xaliproden(10) are of interest, but require further studies to determine if there is a
reproducible reduction of neurotoxic symptoms and no adverse effect on tumor control. In
the absence of a modulator of neurotoxicity, prospective identification of the specific
patients at greatest risk for this adverse event would allow informed decisions on therapy
selection.
Previous studies designed to identify clinically-relevant genetic factors associated with
chemotherapy-induced neurotoxicity have typically explored variation in genes related to
the drug disposition or other drug related pathways.(11-14) The lack of a replication strategy
has limited the utility of the study results.(15)
The purpose of this study was to evaluate the association of genetic variants in prespecified
candidate genes with chemotherapy-induced neurotoxicity. The results of this study provide
a pharmacogenetic model for predicting risk of chemotherapy-induced neurotoxicity and
identify potential targets for therapeutic intervention.
METHODS
Patients and Clinical Data
The Scottish Randomized Trial in Ovarian Cancer (SCOTROC1) trial randomized 1077
patients with locally advanced or metastatic ovarian cancer to treatment with either
docetaxel-carboplatin (n=539) or paclitaxel-carboplatin (n=538).(16) Correlative science
studies, including germline DNA, were prospectively obtained and available from 914
individuals.(11) All patients provided written informed consent. Details of the SCOTROC1
trial (NCT00003998), patient characteristics, treatment outcomes, and toxicities for each
treatment arm were previously described(16). Of particular relevance to this report, the
presence of sensory neuropathy was graded prior to each cycle of chemotherapy, using the
NCI-CTC ordinal assessment system that continues to be the standard for large oncology
clinical trials. Data was not collected on the degree and timing of reversibility of the
peripheral neuropathy phenotype. Patients had not received previous chemotherapy and did
not have clinically detected peripheral neuropathy prior to initiation of therapy.
Candidate-Gene Association Study Design
A total of 60 candidate genes were chosen from three categories: nerve-related genes,
inherited peripheral neuropathy genes, and drug-related genes (Supplemental Table 1).
These genes were derived from studies of platinum/taxane pharmacology, dorsal root
ganglia biology, inherited peripheral neuropathy discovery, or genome-wide association
literature conducted in human subjects.(5, 17, 18) An Illumina GoldenGate custom SNP
array (Illumina, San Diego, CA) with 1536 SNPs was designed based on linkage
disequilibrium, putative function, and prior literature evidence of effect on gene function.
(Supplemental Table 2).
Genotyping
DNA was extracted from whole blood samples obtained prior to the start of therapy.
Genotyping of the 1536 SNP array was performed by the Duke University Center for
Human Genetics Molecular Genetics core facility using methods that have been previously
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described(19) and was analyzed used the Illumina Beadstudio software. An additional 33
SNPs that were not suitable for the Illumina array were genotyped using pyrosequencing
(Biotage, Uppsala, Sweden).(11) Two SNPs were assessed using Taqman® Allelic
Discrimination assays (Applied Biosystems) as previously described. (17)
Data Analysis
Patients that had less than 90% overall complete genotype information were removed (101
patients), as were patient with a lack of neurotoxicity information (5 patients), for a final
n=808. SNPs that had less than 90% overall complete patient information or demonstrated
significant deviations from Hardy-Weinberg equilibrium (p<.05 based on the results of a
chi-square test for independence after Bonferroni corrections) were removed (resulting in
1261 final SNPs).
In order to prevent confounding due to population stratification, Principle component
analysis was performed on these 1261 high quality SNPs.(20) Principle component analysis
confirmed the homogeneity of the SCOTROC1 patient cohort. Subsequently, logistic
regression with step-wise selection was utilized to determine clinical covariates that were
associated with neurotoxicity: ECOG performance status, grade of GI toxicity, and treatment
arm. Time to the first cycle at which ≥ grade 2 neuropathy was experienced was included as
a covariate in the discovery phase only to reduce variability and improve power to detect
genetic variations associated with toxicity (no matter how long it took to experience the
toxicity). Only the clinical covariates of ECOG performance status and treatment arm were
included in all subsequent association analyses (Table 1); the full distributions of all clinical
characteristics can be seen in Supplemental Table 3.
In order to assess which SNPs were associated with moderate to severe neurotoxicity, we
compared individuals with moderate to severe neurotoxicity (NCI-CTC grade 2-4) to those
with mild or no neurotoxicity (NCI-CTC grade 0-1) under a case/control framework. From
the overall available population, test and replication datasets were created by randomization
to contain 50% of the cases and 50% of the controls. Each cohort had 404 patients, with
cases (grades 2/3/4 neurotoxicity) = 91 and controls (grades 0/1 neurotoxicity) = 313. All
SNPs were first evaluated in the testing cohort, and those declared nominally significant
were evaluated in the replication cohort. To determine single-locus association with case/
control status, logistic regression was utilized for each SNP including important clinical
covariates using genotypic encoding rather than assuming an additive genetic model.
Logistic regression was first performed on the test cohort, and SNPs with nominal p-values
<0.05 were assessed in the replication cohort and were considered significant replications if
p<0.05 in the replication set. To further reduce potential false positive findings, only the
SNPs which met these criteria and were consistent in direction of the risk effect for each
genotype (positive vs. negative estimated odds ratio) were considered true replications. For
each replicating SNP, we selected the most likely genetic model for risk by fitting additive,
dominant, recessive and genotypic models and selecting the model which maximized the
likelihood, or equivalently minimized the model deviance. From this model we were able to
determine the risk genotypes for each SNP.
To correct for the multiple comparisons made and to account for the possibility of false
positive findings and the multistage analysis procedure, we carried out permutation testing
to obtain a distribution of joint p-values for our initial association analysis and a distribution
of p-values for the subsequent analysis of risk genotype score (described below), and
corrected p-values were calculated from these distributions. A total of 1000 permuted data
sets were generated by permuting neurotoxicity case/control status and repeated our entire
analysis procedure including our two-stage association analysis, our determination of risk
genotype, and analysis of risk genotype score on each of the 1000 datasets. Only SNPs with
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corrected p-values corresponding to a family-wise error rate of 0.05 were considered
statistically significant.
Once the significant SNPs and most plausible genetic model were determined, we further
quantified the effect due to each SNP using Population Attributable Risk (PAR). PAR is the
proportion of the incidence of severe neurotoxicity in the population that is due to the risk
genotype (the reduction in incidence of severe neurotoxicity that would be observed if the
risk genotype were not present). The PAR for each SNP as well as the cumulative PAR for
all significant SNPs can be calculated as follows:
where ORi is the odds ratio of the risk genotype for SNP i and pi is the prevalence of the risk
genotype for SNP i (21, 22).
To explore the cumulative effect of all significant SNPs, we calculated a neurotoxicity risk
genotype score for each individual which was equal to the number of risk genotypes across
all significant SNPs. We fitted a logistic regression model on the number of risk genotypes,
as well as the important clinical covariates to reduce possible confounding effects of the
covariates on toxicity. A significant result for risk genotype score would indicate a trend in
the number of risk genotypes; as number of risk genotypes increases, the odds for
developing severe neurotoxicity also increase. We performed the assessment with only the
variables that would be known prior to the start of therapy (including ECOG status and
treatment arm) to assess a clinical prediction model. The strength of the clinical prediction
model was evaluated using area under the curve (AUC) analysis, comparing a model with
clinical predictors only to a model also including SNPs.
We also investigated whether the individual SNPs significantly associated with
neurotoxicity and the composite risk genotype score were associated with both survival time
and progression free survival time in the full cohort using a Cox Proportional Hazards model
which included the significant clinical covariates to control for confounding. All data
analysis was performed in R-software (http://www.r-project.org/).
RESULTS
ECOG performance status (OR=1.42, p=0.006) and grade of GI toxicity (OR=1.42,
p=0.001) were associated with increased risk of grade 2+ neurotoxicity, and docetaxel
treatment (OR=0.30, p=7E-11) was associated with reduced risk of grade 2+ neurotoxicity,
independently of SNP associations (See Table 1, Supplementary Table 3 for distributions of
clinical characteristics).
From the 1261 SNPs which passed quality control standards, 69 SNPs were significantly
associated with grade 2+ neurotoxicity in the test patient cohort at the p<0.05 level (Figure
1; Supplemental Table 4). Of those significant in the test cohort, five were also significant in
the replication cohort. Four of these SNPs were consistent in the direction of clinical effect
in the independent test and replication analyses (Table 2). The variants were in BCL2,
SOX10, OPRM1, and TRPV1. All four SNPs reside on different chromosome, and there
was no long-range linkage disequilibrium between these four SNPs, indicating that these are
independent genetic effects (R2<0.0023 for all pairwise combinations of SNPs).
Furthermore, none of the four SNPs were associated with ECOG performance status or
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treatment arm (p>0.05). The Population Attributable Risk (PAR) for each of the four SNPs
varied from 5 to 35% (Table 3). Individuals with 0 risk genotypes have a reduction in
incidence of neurotoxicity of 62% compared to individuals with all 4 risk genotypes (Table
3), although only four patients had all 4 genotypes (Table 4).
After calculating a risk genotype composite score for each individual (equal to the number
of risk genotypes that individual carries), a strong association between the number of risk
genotypes and neurotoxicity was observed (Figure 2A). The number of risk genotypes was
associated with a multiplicative increase in the odds of developing neurotoxicity, with the
odds of developing neurotoxicity estimated to increase by an average of 1.64 for every
subsequent risk variant (p=0.007 after permutation correction) (Table 5). Patients with a
composite score of 4 had an estimated odds ratio for neurotoxicity of 7.41 (3.14-17.46)
compared to individuals with a composite score of 0. Incorporating the genotype risk score
improved the strength of our predictive model, measured by the AUC with clinical
predictors only (Discovery=0.685; Replication=0.664) as compared to the addition of the
genotype risk score (Discovery=0.726; Replication=0.694).
Patients with a high risk genotype score (3-4 risk genotypes) had the same progression free
survival (p=0.75) and overall survival (p=0.54) as patients with the lower risk composite
score (0-2 risk genotypes) (Figure 2B and 2C, respectively). Additionally, Cox proportional
hazards analysis for both survival time and progression-free survival for each individual
genotype indicate no association with progression-free or overall survival.
DISCUSSION
An association study of biologically annotated candidate genes identified and replicated four
variants that confer a cumulative risk for chemotherapy-induced neurotoxicity. The percent
population attributable risk calculation for all 4 SNPs indicates a significant reduction in
incidence of neurotoxicity of 62.0% for individuals with no risk genotypes compared to
individuals with all 4 risk genotypes, although possessing all four risk genotypes is very rare
(expected frequency=0.0065). Furthermore, there is a clear cumulative effect of the four
SNPs, with an estimated odds ratio of 7.41 for risk of neurotoxicity in individuals with 4 risk
genotypes in a model that also includes patient ECOG status and discerns between taxanes.
This suggests an ability to determine a heightened risk of neurotoxicity from platinum/
taxane combination chemotherapy prior to administration of therapy. Minimally, this
information would allow an individual patient to make a more informed decision of the risks
and benefits of therapy, including alternate chemotherapy regimens. This is especially
important in the context of advanced disease, where the goal is palliation of the patient and
risk of severe neurotoxicity may be detrimental.
The addition of the risk genotype score improved the predictive ability of our model over the
use of clinical predictors alone (AUC=0.67 vs. 0.71 in the full cohort); it should be noted
that our risk predictive model relies on the assumption that all four SNPs have equal effects,
which may not be the case. To assess this assumption, we investigated a model where the
score was weighted by the odds ratio of each SNP, with little change to the AUC (0.71).
Relatedly, it is unclear whether the classification of risk genotype for each SNP (which was
wild-type homozygous in two cases and heterozygous in two cases) optimally describes the
true nature of the genotype-phenotype relationship or if the use of an assumed genetic model
could outperform this system.
None of the 4 significant SNPs were associated with progression-free survival or overall
survival. This decouples the theoretical link between neurotoxicity and tumor control and
does not support the worry that reducing neurotoxicity risk might also reduce anticancer
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effect. The unlinking of neurotoxicity and response was also recently corroborated in breast
cancer.(23) Indeed, this data suggests that intervention or prevention strategies for platinum/
taxane neurotoxicity based on these four genetic variants are not likely to adversely
influence the efficacy of the chemotherapeutic agent. Knowledge of genetic risk may serve
as a valuable prediction tool so that a patient’s level of acceptance of risk can be calibrated
with approximate level of risk of neurotoxicity based on the number of risk genotypes.
While the overall goal of the current study was discovery and validation of genetic
associations, several interesting covariates that would not be known prior to treatment, and
could not be used in a predictive model, such as time to first cycle of grade 2 neurotoxicity
and grade of gastrointestinal toxicity were identified. These endpoints likely reflect
underlying biological risk that is not captured by the variants assessed in this study. Analysis
of the variants with only treatment arm as a covariate yielded similar results, with similar
effect size estimates and directions, and similar conclusions regarding association with
toxicity and a lack of association with overall survival. This supports future work in
additional cohorts to focus on testing and refining such a predictive pharmacogenomics
model.
BCL2, SOX10, OPRM1, and TRPV1 encompass a broad spectrum of functionalities
including a role in apoptosis, a transcription factor, an opioid receptor, and therapeutic
targets of pain management, respectively. These genes were amongst 58 candidate genes, all
with biologic plausibility for impact on chemotherapy-induced peripheral neuropathy in
humans. However, the mechanism by which the SNPs or genes we identified influences the
development of neurotoxicity is yet to be defined. The variants identified in this study are
not known to have direct functional consequence, as those in BCL2, SOX10, and OPRM1
are intronic and the TRPV1 variant lies outside of the coding region. Additionally, because
these SNPs were chosen as “tagging” SNPs based on the linkage disequilibrium structure, it
is likely that these SNPs are not directly responsible for biological effect, but act as markers
for the important genomic regions. Future studies should try to refine these association
signals through more fine mapping. For example, TRPV family members have recently been
proposed to have effects on chemotherapy-associated neurotoxicity via glutathione pathway
modulation, and using data from Caucasian individuals from the HapMap, we know that the
SNP in TRPV1 is in strong linkage disequilibrium (r2>.8) with several expression
quantitative trait loci (according to data provided in SCANdb, www.scandb.org)).(24, 25)
While functional understanding is desired, the replication of these SNPs in this study
prepares the way for clinical intervention studies.
All patients in this study were treated with either docetaxel-carboplatin or paclitaxel-
carboplatin combination therapy, with approximately equal numbers randomized to both the
discovery and replication cohorts; however, paclitaxel and docetaxel may have different
genetic markers of neurotoxicity. To evaluate this possibility, we separately examined each
of the four SNPs stratified by treatment group, which yielded similar results (although less
stable due to the reduced sample size), suggesting that the identified SNPs are general
markers of platinum/taxane-induced neurotoxicity. Furthermore, because our full patient
cohort was treated with combination platinum/taxane chemotherapy and both drug classes
independently have been shown to cause neurotoxicity, it is possible that the neurotoxicity
could result from either or both of the drugs. The genes identified in this study are not
unique to the mechanism of action of either platinum (DNA adduct formation) or taxanes
(inhibit microtubule dynamics), therefore, it cannot be assumed that this genetic risk model
for neurotoxicity will be predictive in other contexts. Indeed, the recently replicated
associations of FGD4 and CYP2C8*3 with paclitaxel-associated neurotoxicity(17, 26) were
not observed in SCOTROC1 patients receiving the combination of carboplatin and
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paclitaxel, suggesting that predictive biomarkers may be unique to the drug combinations
being deployed.(11)
Several limitations of this post hoc analysis of a completed clinical study should be
considered. The primary objective of the SCOTROC1 trial was not to assess peripheral
neuropathy, and thus some potentially useful data is not as thoroughly established, including
baseline incidence of neuropathy or other known clinical risk factors such as diabetes. Also,
the neuropathy phenotype was collected exclusively by clinician reporting using the
standard NCI-CTC scale. While this scale is still the industry standard for international
cancer clinical trials, more sensitive scales that incorporate patient assessment have been
developed to overcome this challenge.(27) Objective neuropathy measurement using nerve
conduction or other surrogate metrics may be an even more sensitive technique for
collecting this phenotype in future studies, should these methods be refined to use in the
context of routine oncology practice. Unfortunately it is extraordinarily difficult and
expensive to prospectively collect comprehensive toxicity data in large multicenter clinical
trials and impossible to collect it retrospectively.
This study is a first step in defining a pharmacogenetic risk model for this treatment limiting
side-effect of platinum-taxane chemotherapy.(28) This gives a basis for studies that further
validate this risk model in independent patient cohorts to identify the power of this model to
predict chemotherapy-induced neurotoxicity as well as to evaluate the utility of these genes
as therapeutic targets.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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STATEMENT OF TRANSLATIONAL RELEVANCE
The ability to predict which patients are at highest risk of chemotherapy-induced
peripheral neuropathy would enable clinicians to make more informed treatment
decisions. This association study of credentialed candidate genes found and replicated 4
single nucleotide polymorphisms that can categorize an ovarian cancer patients’ risk of
neuropathy when treated with platinum/taxane combination therapy. Patients possessing
3 risk variants have 4.5 times greater risk of neuropathy compared with individuals with
no risk variants. The variants did not associate with overall survival. These variants are
ready for confirmatory prospective studies to validate the utility in neuropathy risk
stratification. Patients who are predicted to be at high risk could be offered alternative
treatment options that are similarly effective but safer for those individuals.
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Flowchart of the study design, including SNP QC and the narrowing number of SNPs per
stage, in addition to patient characteristics.
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Relationship between genotype risk score (0-2 vs 3-4) and (A) incidence of neurotoxicity (+/
− 2 standard errors), (B) progression free survival (p=0.75) or (C) overall survival (p=0.54)
in the full dataset.
McWhinney-Glass et al. Page 12

























McWhinney-Glass et al. Page 13
Table 1









0 285 35.3% 142 35.1% 143 35.4%
1 341 42.2% 171 42.3% 170 42.1%
2 135 16.7% 66 16.3% 69 17.1%
3 44 5.4% 23 5.7% 21 5.2%
4 3 0.4% 2 0.5% 1 0.2%
Worst grade of
GI toxicity
0 37 4.6% 18 4.5% 19 4.7%
1 212 26.2% 116 28.7% 96 23.8%
2 416 51.5% 201 49.8% 215 53.2%
3 130 16.1% 62 15.3% 68 16.8%




0 268 33.2% 119 29.5% 149 36.9%
1 426 52.7% 221 54.7% 205 50.7%
2 114 14.1% 64 15.8% 50 12.4%
Treatment
Paclitaxel/Carbo
platin 400 49.5% 206 51.0% 194 48.0%
Docetaxel/Carbo
platin 408 50.5% 198 49.0% 210 52.0%
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Table 3
Percent population attributable risk (PAR) for each SNP and cumulative PAR based on OR estimates in Table
1, adjusted for ECOG status and treatment arm.
rs139887 rs2849380 rs544093 rs879207 All SNPs
PAR (%) 19.6 5.6 35.2 22.8 62.0
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Table 4
Frequencies (percentages) of cases and controls in each genotype risk category.
Genotype
Risk Score
0 1 2 3 4 Total
Cases 3 (6%) 41 (17%) 85 (26%) 48 (31%) 3 (75%) 180
Controls 45 (94%) 202 (83%) 244 (74%) 107 (69%) 1 (25%) 599
Total 48 243 329 155 4 779
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Table 5










Model with only a
priori covariates
Odds Ratio






0 0.06 0.94 - - -
1 0.17 0.83 1.64 (1.3313, 2.0442) 0.007
2 0.26 0.74 2.72 (1.7724, 4.1789) -
3 0.31 0.69 4.49 (2.3597, 8.5427) -
4 0.75 0.25 7.41 (3.1415, 17.4632) -
*
Both ECOG performance status and treatment arm were utilized as covariates and were determined to be associated with neurotoxicity.
Neurotoxicity risk increases per ECOG performance category (OR=1.45, 95% CI 1.11-1.89, uncorrected p=0.00631) and patients undergoing
docetaxel-carboplatin treatment were at a reduced risk of developing neurotoxicity (OR=0.30, 95% CI 0.21-0.43, uncorrected p=8×10−11).
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